Additional Resources
Top Commentators:
- Elliott Abrams
- Fouad Ajami
- Shlomo Avineri
- Benny Avni
- Alan Dershowitz
- Jackson Diehl
- Dore Gold
- Daniel Gordis
- Tom Gross
- Jonathan Halevy
- David Ignatius
- Pinchas Inbari
- Jeff Jacoby
- Efraim Karsh
- Mordechai Kedar
- Charles Krauthammer
- Emily Landau
- David Makovsky
- Aaron David Miller
- Benny Morris
- Jacques Neriah
- Marty Peretz
- Melanie Phillips
- Daniel Pipes
- Harold Rhode
- Gary Rosenblatt
- Jennifer Rubin
- David Schenkar
- Shimon Shapira
- Jonathan Spyer
- Gerald Steinberg
- Bret Stephens
- Amir Taheri
- Josh Teitelbaum
- Khaled Abu Toameh
- Jonathan Tobin
- Michael Totten
- Michael Young
- Mort Zuckerman
Think Tanks:
- American Enterprise Institute
- Brookings Institution
- Center for Security Policy
- Council on Foreign Relations
- Heritage Foundation
- Hudson Institute
- Institute for Contemporary Affairs
- Institute for Counter-Terrorism
- Institute for Global Jewish Affairs
- Institute for National Security Studies
- Institute for Science and Intl. Security
- Intelligence and Terrorism Information Center
- Investigative Project
- Jerusalem Center for Public Affairs
- RAND Corporation
- Saban Center for Middle East Policy
- Shalem Center
- Washington Institute for Near East Policy
Media:
- CAMERA
- Daily Alert
- Jewish Political Studies Review
- MEMRI
- NGO Monitor
- Palestinian Media Watch
- The Israel Project
- YouTube
Government:
Back
(RealClearDefense) Lt.-Col. (ret.) Dr. Arik Eisenkraft - Acute radiation syndrome (ARS) may be the result of an accident with diagnostic and therapeutic devices, or with a nuclear facility (Chernobyl, Fukushima). It may also be the result of an intentional act of terrorism, involving the use of a radiological dispersal device (i.e., dirty bomb), an improvised nuclear device, an attack on a nuclear power plant, or any number of potential scenarios. The major goals of a response plan to a radio-nuclear emergency are to protect the public, as well as the emergency personnel while performing their duties. A novel protection device that recently reached the market is the StemRad 360 Gamma wearable shield, which allows the protection of enough bone marrow tissue among first responders and all those who may be exposed to high radiation levels in a way that will ensure their survival. The first 36-48 hours following exposure are critical. There is a time window allowing for treatment even in a mass casualty scenario. Pluristem Therapeutics Inc. is developing cell therapy products that release a mix of therapeutic proteins in response to signals from cells and tissues that have been damaged by conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. The writer was former Head of Medicine for the Israel Ministry of Defense, where he led studies and product development for chemical, biological, radiological, and nuclear (CBRN) medical countermeasures.2017-08-10 00:00:00Full Article
Israel Developing Ways to Survive Nuclear Radiation
(RealClearDefense) Lt.-Col. (ret.) Dr. Arik Eisenkraft - Acute radiation syndrome (ARS) may be the result of an accident with diagnostic and therapeutic devices, or with a nuclear facility (Chernobyl, Fukushima). It may also be the result of an intentional act of terrorism, involving the use of a radiological dispersal device (i.e., dirty bomb), an improvised nuclear device, an attack on a nuclear power plant, or any number of potential scenarios. The major goals of a response plan to a radio-nuclear emergency are to protect the public, as well as the emergency personnel while performing their duties. A novel protection device that recently reached the market is the StemRad 360 Gamma wearable shield, which allows the protection of enough bone marrow tissue among first responders and all those who may be exposed to high radiation levels in a way that will ensure their survival. The first 36-48 hours following exposure are critical. There is a time window allowing for treatment even in a mass casualty scenario. Pluristem Therapeutics Inc. is developing cell therapy products that release a mix of therapeutic proteins in response to signals from cells and tissues that have been damaged by conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. The writer was former Head of Medicine for the Israel Ministry of Defense, where he led studies and product development for chemical, biological, radiological, and nuclear (CBRN) medical countermeasures.2017-08-10 00:00:00Full Article
Search Daily Alert
Search:
|